-+ 0.00%
-+ 0.00%
-+ 0.00%

Truist Securities Maintains Buy on Maze Therapeutics, Lowers Price Target to $64

Benzinga·04/14/2026 13:53:13
Listen to the news
Truist Securities analyst Danielle Brill maintains Maze Therapeutics (NASDAQ:MAZE) with a Buy and lowers the price target from $68 to $64.